Cyclacel Announces Closing of $20 Million Public Offering
24 avr. 2020 16h05 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., April 24, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing...
Cyclacel Announces Reverse Stock Split
14 avr. 2020 12h30 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., April 14, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing...
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results
26 févr. 2020 16h05 HE
|
Cyclacel
– Anticancer Activity of Fadraciclib (CYC065) Monotherapy in Patients with MCL1 Amplified Solid Tumor and Fadraciclib-venetoclax Combination in Patients with Relapsed or Refractory AML/MDS and CLL – ...
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2019 Financial Results
19 févr. 2020 07h00 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Cyclacel Pharmaceuticals Reviews 2019 Achievements and Announces Key Business Objectives for 2020
13 janv. 2020 07h00 HE
|
Cyclacel
– Anticancer Activity of CYC065 Monotherapy in Patients with MCL1 Amplified Solid Tumors and CYC065-venetoclax combination in AML/MDS and CLL dose escalation studies – BERKELEY HEIGHTS, N.J., Jan. ...
Cyclacel Pharmaceuticals Reports Third Quarter 2019 Financial Results
13 nov. 2019 16h05 HE
|
Cyclacel
– Investigator-Reported Partial Response in Phase 1 Study of CYC065 as Single Agent – – Conference Call Scheduled November 13, 2019 at 4:30 p.m. ET – BERKELEY HEIGHTS, N.J., Nov. 13, 2019 (GLOBE...
Cyclacel Pharmaceuticals Announces Multiple Clinical Abstracts Selected for Presentation at the ASH 2019 Annual Meeting
06 nov. 2019 09h00 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2019 Healthcare Conference
23 sept. 2019 07h00 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing...
Cyclacel Pharmaceuticals Announces First Patient Treated With Oral CYC065 in a Phase 1 Study in Patients With Advanced Solid Tumors
09 sept. 2019 07h00 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., Sept. 09, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Cyclacel Pharmaceuticals to Release First Quarter 2019 Financial Results
08 mai 2019 07h00 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., May 08, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...